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The purpose of this paper is to discuss whether the
randomized clinical trial (RCT) is indeed the gold standard
among epidemiological studies. This paper illustrates to what
extent different study designs may contribute to the answer
of the following therapeutic research question based on a
study of Wanner et al.: ‘Is the use of a statin associated to less
cardiac mortality in patients with type 2 diabetes mellitus
who receive hemodialysis?’ If a therapeutic study is feasible,
like the research question of the clinical example, the RCT is
almost unbeatable: the problems that may occur in the other
study designs do not exist or to a lesser extent using an RCT.
The main advantage of an RCT is that the randomization
procedure helps to prevent selection bias by the clinician by
breaking the link between the clinician’s therapy prescription
and the patient’s prognosis. Within observational studies,
however, selection by the clinician may occur, and, even after
adjustment for potential confounders in the statistical
analysis, it may not be possible to make a fair comparison
between the groups. Usually, results from observational
studies are needed to come to a hypothesis that can
subsequently be tested within an RCT. Moreover,
observational data are most often more useful than RCTs
for non-therapeutic studies.
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Clinical epidemiological studies often investigate whether an
exposure, for example a medical intervention, gene, or
environmental factor, is related to the development or
progression of a disease. To address these research questions,
clinical epidemiology makes use of different study designs
(Figure 1). The purpose of this paper is to discuss whether
the randomized clinical trial (RCT) is indeed the gold
standard among epidemiological studies. In order to illus-
trate to what extent different study designs may contribute to
the answer of a research question, the study of Wanner et al.1
was used as an example.
CLINICAL EXAMPLE
Some years ago, Wanner et al. wanted to address the problem
of increased risk of cardiovascular disease and mortality
in hemodialysis patients with type 2 diabetes mellitus. They
already knew that statin treatment reduced the incidence of
cardiovascular disease and mortality in patients with and
without type 2 diabetes mellitus2,3 and now wanted to
investigate whether this was also true for patients with type 2
diabetes mellitus undergoing hemodialysis. Although the
authors made the choice for an RCT, this paper focuses on
the advantages and disadvantages of different study designs
to obtain an answer to their question. For the purpose of this
paper, their research question was simplified into ‘Is the
use of a statin associated to less cardiac mortality in patients
with type 2 diabetes mellitus who receive hemodialysis?’. In
this perspective, the use of the statin can be regarded as the
exposure and cardiac mortality as the outcome.
HOW CAN DIFFERENT STUDY DESIGNS ADDRESS THIS
PROBLEM?
Case report and case series
A case report or case series usually describes a new
mechanism, or a new aetological or therapeutic observation
in one or a few patients. In general, these reports compare
new observations with consolidated medical experience.4
In 1990, Di et al.5 published a case series on the preventive
effect of statins on hyperlipidemia in eight patients under-
going continuous ambulatory peritoneal dialysis. One thing
this case series showed was a decrease of mean fasting plasma
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concentrations of total cholesterol from 280.5 to 190.2 mg/dl
in 4 weeks, and a decrease of mean plasma low-density
lipoprotein concentrations from 257.6 to 190.5 mg/dl. They
concluded that statins appeared to be a promising class
of drugs for the effective control of hyperlipemia in hyper-
cholesterolemic patients, and these drugs may reduce
cardiovascular morbidity in continuous ambulatory peri-
toneal dialysis patients.
Although similar case reports and case series would not
provide a definitive answer to the question whether a statin
reduces cardiac mortality in type 2 diabetes patients on
hemodialysis, the observations may fit the hypothesis and
may lead to important progress in medical scientific know-
ledge. The study of Di et al., for instance, was important to
generate ideas for further studies.
Cross-sectional study
In cross-sectional studies, the variables (e.g. patient and
treatment characteristics and the outcome variable) are
assessed at one point in time or over a short period. It
would not be possible to perform a cross-sectional study to
answer our specific research question, because dead people
cannot be included into cross-sectional studies (as exposure
and outcome must be measured simultaneously). A cross-
sectional study could, however, be performed when the
outcome would have been cardiac disease instead of cardiac
mortality.
Such a study was performed by Miller et al.6 who assessed
the use of statins (and other cardioprotective medication),
diabetic status, and the existence of coronary artery disease in
185 hemodialysis patients. Patients with coronary artery
disease were more likely to be on a statin (circa 61%) than
those without coronary artery disease (circa 35%). Although
this study might suggest that statins cause dyslipidemia or
even cardiac disease, this cannot be concluded. An important
reason for this is that it is not known whether the exposure to
statins occurred before, during, or after the onset of disease as
these measurements were performed simultaneously. The
presence of dyslipidemia and/or cardiac disease might have
prompted renal clinicians to the prescription of these drugs.
Moreover, if the exposure has a lethal effect, patients with the
exposure may already have died before the study, which may
underestimate results within cross-sectional studies.
Although cross-sectional studies cannot provide a definite
answer to the question whether a statin is related to cardiac
disease in type 2 diabetes mellitus patients on hemodialysis,
such studies might be relatively inexpensive and may take up
little time to examine whether the results fit the hypothesis.
Cross-sectional studies showing a potential association can
be improved by studies assessing the exposure before the
outcome.
Case–control study
In a case–control study, patients are selected on the basis of
the outcome variable (e.g. cardiac death). In patients who
have developed the outcome of interest (cases), the exposure
status (e.g. use of statins) is determined by looking backward
in time. In addition, the exposure frequency is determined in
a control group, usually consisting of people who have not
developed the outcome of interest (controls). Then exposure
frequencies are compared between cases and controls.
To our knowledge, there is no published case–control
study focusing on our specific research question. A hypo-
thetical case–control study could use the patients with
type 2 diabetes mellitus on hemodialysis who died within
5 years after the start of hemodialysis, as cases. The use of
statins can be determined by looking backward in time,
using, for example, medical records. The results may show
that a small proportion of these patients used statins. But
then the question is how many of the patients with type 2
diabetes mellitus on hemodialysis who survived for 5 years
used a statin? This answer can be provided by a control
group. If the cases would be derived from a number of
dialysis centers, a potential suitable control group would
consist of patients of the same dialysis centers who survived
for 5 years. Also in those controls, the use of a statin would be
determined by looking backward in time.
Results may show that the proportion of patients using a
statin was lower in the cases compared with the controls.
Although results from this study would then suggest that
there is an inverse relationship between statin treatment and
cardiac mortality in patients with type 2 diabetes mellitus on
hemodialysis, again one should be cautious to conclude this.
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Figure 1 | Overview of clinical epidemiological study designs.
Classification is made with regard to the time sequence in which the
exposure and outcome are studied.
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The main reason for this is selection by prognosis: the
clinician decides who will receive statin therapy, and
his opinion about the patient’s prognosis may guide his
prescription. For example, if a clinician prescribes a statin
more often to younger patients as he believes that this drug is
more effective in younger patients, the groups are not similar
with respect to age. Adjustment for potential confounders in
the statistical analysis may not be sufficient, because it is not
possible to adjust for confounders that are not measured (or
not known) and confounders may be measured insufficiently
(e.g. not taken into account the duration or severity of
smoking). This means that even after adjustment for
potential confounders, it may not be possible to make a fair
comparison between cases and controls. Furthermore, the
exposure may be better reported in the cases than in the
controls or vice versa. This phenomenon is called recall bias
and may cause invalid results, especially in case–control
studies. However, in our hypothetical case–control study,
there is no reason to assume that the statin history was
reported differently in the medical records of the cases and
controls.
A case–control study is often performed if the outcome
under study is rare. In our example, the outcome variable
(cardiac mortality) is not very rare in patients with type 2
diabetes mellitus on hemodialysis, and our research question
can therefore also be answered using a cohort study.
Cohort studies
Within a cohort study, a researcher composes a cohort of
patients (e.g. patients on hemodialysis with type 2 diabetes
mellitus) who are free of the outcome of interest. The
exposure variable (e.g. use of statin) will be assessed at the
start of the study. Patients from this cohort will be followed
over time to assess who will develop the outcome (e.g.
cardiac death) and who will not.
The Dialysis Outcomes and Practice Patterns Study
performed a cohort study investigating whether statins
reduce (cardiovascular) mortality in hemodialysis patients.7
The cohort, including patients who were prescribed statins
and patients who were not, was followed over a period to
examine who died. Statins were associated with a 23% lower
cardiac mortality risk. The results suggested that patients
using statins had a lower risk of cardiac death compared with
those who did not use statins.
This cohort study suggested that statins may prevent
cardiac death in hemodialysis patients. One should, however,
still be careful to conclude that statin use is associated with
reduced cardiac mortality in hemodialysis patients, because,
as in the case–control study, selection by prognosis may have
occurred.
Randomized clinical trial
An RCT is a special kind of cohort study, with the
characteristic that patients are randomly assigned to the
experimental group (with exposure) and the control group
(without exposure). In our example, randomization will
prevent the clinician from deciding who will receive a statin
and who will not, as only chance will decide to which group
patients will be allocated. Therefore, randomization helps to
prevent selection by the clinician, and helps to establish
groups that are equal with respect to relevant prognostic
factors. It should be noted, however, that even after
randomization the two groups may not be equal in all
prognostic factors (this is even unlikely given the variety in
genotypes): remaining differences may occur by chance.
When feasible, it is strongly recommended that also
after randomization, patients and clinicians do not know
who receives the intervention and who does not. Studies
may be single blind (either the patient or the clinician does
not know who receives the treatment and who does not) or
double blind (both the patient and the clinician do not
know who receives the treatment). One reason for ‘blinding’
is that the patient as well as the clinician may act differently
if they know about treatment allocation. For instance, the
clinician may tend to prescribe another medicine to the
‘untreated’ patients who receive a placebo, which may in
turn influence the outcome in the control group. The other
reason is that the outcome variable should be determined
independently to prevent information bias, that is, to
prevent for instance that the event is more often reported
in the placebo group. For example, the clinician may (in
case of doubt) tend to report more often the diagnosis of
cardiac death if a patient is included in the placebo group
than if this patient would have been included in the
experimental group.
Wanner et al.1 used a double-blind RCT to investigate
whether atorvastatin was associated with less cardiovascular
disease and mortality in patients with type 2 diabetes mellitus
on hemodialysis. The primary end point was a composite of
death from cardiac causes, fatal stroke, nonfatal myocardial
infarction, or non-fatal stroke, whichever occurred first.
During a median follow-up period of 4 years, 469 of 1255
patients reached the primary end point, 226 of whom were
assigned to atorvastatin and 243 to placebo. The results
showed that atorvastatin had no effect on the primary end
point (relative risk, 0.92; 95% confidence interval 0.77–1.10).
Using a double-blind RCT, any differences in outcome can
reasonably be attributed to the effect of the exposure.
However, in their RCT, Wanner et al. found no difference
in outcome between the experimental and control group, and
therefore, they concluded that atorvastatin did not prevent
the primary end point. In addition to this perhaps
unexpected result, a few issues may be relevant. First, if
more patients had been included in the study, the small effect
might have become statistically significant, although such an
effect would probably have remained small, that is not highly
clinically relevant. Second, a number of patients were not
included in the study, which has compromised the generali-
zability of the results at least to some extent. Such ‘limi-
tation’ applies to all RCTs where, in many cases, inclusion
and exclusion criteria narrow down the cohort to a very
selected group.
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IS THE RCT AN UNBEATABLE STANDARD IN CLINICAL
RESEARCH?
Many people would agree that for a therapeutic research
question like our clinical example, the RCT is the most
appropriate study design. If a therapeutic study is feasible
(e.g. no ethical problems, sufficient number of patients can
be included, affordable, feasible follow-up period), the RCT is
almost unbeatable: the problems that may occur in the other
study designs do not exist or to a lesser extent using an RCT.8
The main advantage of an RCT is that the randomization
procedure helps to prevent selection by the clinician.
Although randomization helps, but certainly does not
guarantee to make all else equal for measured and unmea-
sured variables, it guarantees that any differences occur by
chance. Within observational studies, however, selection by
prognosis may occur, and adjustment for potential con-
founders in the statistical analysis may not be sufficient to
make a fair comparison between the groups. However, results
from observational studies are usually needed to come to a
hypothesis that can subsequently be tested within an RCT.
Moreover, observational data are most often more useful
than RCTs for non-therapeutic studies. The next article in
this series will describe the strengths of observational studies
in more detail.
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